Medifast (NYSE:MED) Releases Q1 2025 Earnings Guidance

Medifast (NYSE:MED) issued an update on its first quarter 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of -0.500-0.000 for the period, compared to the consensus estimate of -0.190. The company issued revenue guidance of $100.0 million-$120.0 million, compared to the consensus revenue estimate of $130.8 million.

Medifast Stock Performance

MED traded down $0.16 on Tuesday, hitting $16.05. The company’s stock had a trading volume of 280,528 shares, compared to its average volume of 212,304. The company’s 50 day simple moving average is $16.61 and its 200-day simple moving average is $18.05. The firm has a market cap of $175.55 million, a P/E ratio of 24.32 and a beta of 1.14. Medifast has a 12 month low of $14.76 and a 12 month high of $49.90. The company has a quick ratio of 2.55, a current ratio of 3.11 and a debt-to-equity ratio of 0.06.

Medifast (NYSE:MED) last posted its earnings results on Tuesday, February 18th. The specialty retailer reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.26. Medifast had a net margin of 1.09% and a return on equity of 15.98%. Analysts forecast that Medifast will post 1.68 EPS for the current year.

Wall Street Analyst Weigh In

Separately, DA Davidson upgraded shares of Medifast from an “underperform” rating to a “neutral” rating and increased their target price for the stock from $16.50 to $17.00 in a research note on Tuesday, November 5th.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.